nabiximols (Sativex)

a combination of the above cpds for treatment of multiple sclerosis pain

Also Known As:

Sativex; GW 1000; GW-1000; GW1000; SAB 378; SAB-378; SAB378; tetrahydrocannabinol-cannabidiol combination; (6aR,10aR)-6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo(c)chromen-1-ol - 2-((1R,6R)-6-isopropenyl-3-methyl-3-cyclohexen-1-yl)-5-pentyl-1,3-benzenediol (1:1)

Networked: 214 relevant articles (42 outcomes, 80 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Vila Silván, Carlos: 9 articles (01/2022 - 12/2020)
2.	Copeland, Jan: 7 articles (01/2022 - 03/2014)
3.	Sessa, Edoardo: 7 articles (08/2020 - 01/2015)
4.	Essner, Ute: 6 articles (02/2024 - 12/2020)
5.	Centonze, Diego: 6 articles (01/2022 - 10/2009)
6.	Lintzeris, Nicholas: 6 articles (01/2022 - 03/2014)
7.	Bramanti, Placido: 6 articles (08/2020 - 01/2015)
8.	Fernández-Ruiz, Javier: 6 articles (03/2017 - 09/2011)
9.	Bruno, Raimondo: 5 articles (01/2022 - 01/2018)
10.	Montebello, Mark: 5 articles (01/2022 - 03/2014)

Related Diseases

1.	Multiple Sclerosis 11/01/2015 - "Despite the proven efficacy of Sativex(®) (9-delta-tetrahydrocannabinol plus cannabidiol) oromucosal spray in reducing spasticity symptoms in multiple sclerosis (MS), little is known about the neurophysiological correlates of such effects. " 11/01/2014 - "Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis." 02/01/2012 - "To evaluate the maintenance of efficacy of Sativex in subjects who have gained long-term symptomatic relief of spasticity in multiple sclerosis (MS), and to assess the impact of sudden medicine withdrawal. " 03/01/2024 - "Data from adult patients with spasticity related to multiple sclerosis (MSS) from two randomized placebo-controlled clinical trials of nabiximols were used as analysis sets. " 07/01/2023 - "To provide a comprehensive assessment of the treatment effects of nabiximols oromucosal spray on multiple sclerosis spasticity in two clinical trials, GWSP0604 and SAVANT. "
2.	Pain (Aches) 05/05/2022 - "The oromucosal spray Nabiximols demonstrated an improvement in reducing MS spasticity, pain, and quality of life with a tolerated adverse effect. " 01/01/2022 - "Compared with placebo, nabiximols probably reduces the severity of spasticity in the short-term in people with MS. We are uncertain about the effect on chronic neurological pain and health-related quality of life. " 01/01/2022 - "Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial." 01/01/2021 - "No treatment-related SAEs were recorded in nabiximols pain studies. " 02/01/2016 - "This real-world study confirms nabiximols efficacy and safety in the treatment of MS-related spasticity and pain, which is maintained up to 48 weeks."
3.	Neuralgia (Stump Neuralgia) 01/01/2016 - "Our data suggest that Sativex may be effective in improving MS-related neuropathic pain, maybe through its action on specific cortical pathways." 01/01/2021 - "Pooled analysis of nabiximols and placebo in randomized controlled studies (RCTs) of chronic neuropathic pain. " 01/01/2021 - "Nabiximols in Chronic Neuropathic Pain: A Meta-Analysis of Randomized Placebo-Controlled Trials." 01/01/2021 - "Larger RCTs designed to assess the effect of nabiximols in neuropathic pain are required to reach more definitive conclusions." 01/01/2021 - "Nabiximols was superior to placebo for reduction of chronic neuropathic pain, with a small effect size. "
4.	Cancer Pain 01/01/2021 - ": This review compiles safety and tolerability data from all published observational studies, registry analyses, and case reports identified in systematic searches in which nabiximols oromucosal spray was investigated for spasticity (n = 20) and/or chronic non-cancer pain (n = 4). " 01/01/2021 - "Serious AE (SAE) rates for nabiximols and placebo were higher in cancer pain (21.8% and 16.9%) than in MS spasticity (4.7% vs. 0.8%) and neuropathic pain (4.1% vs. 3.1%) studies despite similar dose ranges. " 01/01/2021 - "In RCTs, discontinuation rates due to adverse events (AEs) for nabiximols and placebo were lower in spasticity studies (5.4% and 2.8%) than in neuropathic pain (12.9% and 5.3%) or cancer pain (19.5% and 16.6%) studies. " 02/01/2008 - "Numerous randomized clinical trials have demonstrated safety and efficacy for Sativex in central and peripheral neuropathic pain, rheumatoid arthritis and cancer pain. " 12/01/2017 - "Five studies that evaluated THC oil capsules, THC:CBD oromucosal spray (nabiximols), or THC oromucosal sprays found some evidence of cancer pain reduction associated with these therapies. "
5.	Spasm (Spasms) 07/01/2023 - "Nabiximols leads to improvement in spasticity that was sustained over the 12-week treatment period as measured by average daily Spasticity NRS scores, daily spasm counts, and MAS scores for combinations of muscle groups, especially the combination of the 6 key muscle groups in the lower limbs in NRS responders to nabiximols treatment." 01/01/2024 - "In 7 patients who reported spasms, severity was reduced or spasms were absent/unnoticeable during nabiximols treatment. " 07/01/2023 - "Percent reduction in geometric mean change from baseline in average daily spasm count for nabiximols ranged from 19-35% versus placebo. " 09/01/2011 - "Secondary end-points of responder analysis, Spasm Frequency Score, Sleep Disturbance NRS Patient, Carer and Clinician Global Impression of Change were all significant in favour of nabiximols. " 12/01/2021 - "Our single-centre experience highlights that both BTI and nabiximols are effective in treating multiple sclerosis-related spasticity; however, BTI treatment may be more effective on spasms intensity. "

Related Drugs and Biologics

1.	Dronabinol (THC)
2.	nabiximols (Sativex)
3.	Cannabidiol
4.	Opioid Analgesics (Opioids)
5.	Cannabinoids
6.	nabilone (Cesamet)
7.	Neuroprotective Agents
8.	Analgesics (Analgesic Drugs)
9.	Therapeutic Uses
10.	NAD (NADH)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Fat-Restricted Diet (Diet, Fat Restricted)
4.	Withholding Treatment
5.	Analgesia